|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
In this study, we investigated the mRNA expression of the IL-4 receptor (IL-4Ralpha), IL-5Ralpha, GM-CSFRalpha, and IL-12Rbeta2 in biopsy specimens from acute and chronic AD lesions, uninvolved AD skin, normal skin, and psoriatic skin lesions.
|
9723668 |
1998 |
|
Dermatitis, Atopic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
IL-4 mRNA expression was increased in stimulated T cells of children with allergic asthma and atopic dermatitis, but not in those with non-allergic asthma as compared with healthy controls.
|
9199876 |
1997 |
|
Dermatitis, Atopic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The IL-4 -590C/T polymorphism may contribute to AD susceptibility in the overall population and children, especially for Asian children, but large well-designed studies are warranted to confirm this conclusion.
|
28169853 |
2017 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
These result suggest that SCCA is induced in AD skin, probably due to direct actions of IL-4 and/or IL-13 on keratinocytes.
|
16238792 |
2005 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
It has been recently shown that human IL-18 plays a role in atopic dermatitis (AD) by enhancing IL-4 and IL-13 production and by stimulating the synthesis of IgE.
|
17517100 |
2007 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
For the first time, these data show how initial AD lesions convert to chronic inflammation and provide another rationale for targeting IL-4 in patients with AD, a therapeutic approach that is currently under development.
|
24698321 |
2014 |
|
Dermatitis, Atopic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Patients who were carriers of IL4 -590C, IL-4Rα I50V G, STAT6 2964 A and STAT6 2892 T had an increased risk of AD [OR and 95% CI: 3.2 (2.5-4.2), p=0.005].
|
24742632 |
2014 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
As a result of their structural similarity, interleukin-13 and interleukin-4 have overlapping functions in the mediation of type-II-driven diseases and are, therefore, promising targets of biologic drugs currently in development for the treatment of such diseases, including asthma and atopic dermatitis.
|
29411337 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
We show, in this study, that T cell receptor (TCR)-activated T cells from atopic dermatitis (AD) patients proliferate less than control T cells and produce lower amounts of IFN-gamma and IL-2, but comparable amounts of IL-4.
|
15660915 |
2005 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> Dupilumab, a fully human monoclonal antibody targeting the alpha subunit of IL-4 was recently approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adult patients.
|
31647347 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
In the recurrent phase of AD, YPFS exhibited both short- and long-term anti-allergic inflammatory efficacy with reduced ear tissue inflammation and decreased IL-4, IL-5, IL-13, and IgE production.
|
30668371 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Recently, cases of AA healing during treatment with anti-IL4/IL13 monoclonal antibody dupilumab (D) for AD were reported.
|
31306557 |
2019 |
|
Dermatitis, Atopic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our results suggest that IL-18 is correlated with increased of IL-4 levels in SEB-stimulated AD lymphocyte cultures.
|
27543731 |
2017 |
|
Dermatitis, Atopic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our approach was to identify polymorphisms within the promoter regions of IL-4 and test their association with atopic eczema.
|
11496248 |
2001 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
Differential expression of inflammation-related genes in IL-4 transgenic mice before and after the onset of atopic dermatitis skin lesions.
|
26585782 |
2016 |
|
Dermatitis, Atopic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
These data indicate that although acute and chronic AD lesions are associated with increased activation of IL-4 and IL-5 genes, initiation of acute skin inflammation in AD is associated with a predominance of IL-4 expression whereas maintenance of chronic inflammation is predominantly associated with increased IL-5 expression and eosinophil infiltration.
|
8040343 |
1994 |
|
Dermatitis, Atopic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
To assess whether genetic variants of TXA2 receptor, IL-4 and IL-4R alpha genes relate to the elevation of serum immunoglobulin E levels in patients with atopic dermatitis (AD), we conducted an association study of genetic polymorphisms of TXA2 receptor (795C/T), IL-4 (-589C/T), and IL-4R alpha (Ile50Val) in a Japanese population (n = 789).
|
11922633 |
2002 |
|
Dermatitis, Atopic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Increased levels of IL-13 mRNA, but not IL-4 mRNA, are found in vivo in peripheral blood mononuclear cells (PBMC) of patients with atopic dermatitis (AD).
|
9158100 |
1997 |
|
Dermatitis, Atopic
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
In addition, gracillin strongly inhibited PI-induced IL-4 expression in RBL-2H3 cells and in the skins of AD mice.
|
30200442 |
2018 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
CTD_human |
Azole derivatives, ketoconazole, itraconazole, miconazole, and nonazole terbinafine hydrochloride, and tolnaftate reduced interleukin-4 and interleukin-5 secretion without altering that of interferon-gamma and interleukin-2 in anti-CD3/CD28-stimulated T cells from both atopic dermatitis patients and normal donors.
|
11886533 |
2001 |
|
Dermatitis, Atopic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Since the T allele was reported to be associated with increased IL4 gene promoter activity compared with the C allele, our data indicate that genetic differences in transcriptional activity of the IL4 gene influence AD predisposition, particularly in Japanese, because of a high frequency of the T allele.
|
9643293 |
1998 |
|
Dermatitis, Atopic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Our data suggest that the IL13 Arg130Gln polymorphism and haplotypes consisting of IL13 Arg130Gln and IL4 C-589 T were associated with the development of atopy and atopic dermatitis at 24 months of age.
|
12847555 |
2003 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
CTD_human |
Interleukin-4 plus anti-CD40 increased intracellular cAMP by activating cAMP-synthesizing adenylate cyclase in surface IgE- B cells, and the increase was greater in the cells from atopic dermatitis patients than in those from normal donors.
|
12230500 |
2002 |
|
Dermatitis, Atopic
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Recent studies have shown that polymorphisms in the genes for IL-4 receptor α chain (IL4RA) may contribute to susceptibility of AD and JCP, although the differences in the involvements of loci of IL4RA gene between AD and JCP are unclear.
|
21918367 |
2012 |
|
Dermatitis, Atopic
|
0.600 |
Biomarker
|
disease |
BEFREE |
The first highly effective mAb for AD, dupilumab, targets the IL-4/IL-13 receptor and was approved in early 2017 in the United States for moderate-to-severe adult AD.
|
28887947 |
2017 |